GlassScriptPhysician profile
Joseph Kenneth Wong
NPI 1598758120
$11,837.66
in general payments reported to CMS, 2019-2025
37 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,093 · 2020: $1,121 · 2021: $1,878 · 2022: $1,867 · 2023: $1,502 · 2024: $2,048 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,272.60 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,688.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,327.10 | 2019-2025 | Evenity, Repatha, Repatha |
| Amarin Pharma, INC. | $700.05 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $649.56 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $631.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $597.42 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Pfizer INC. | $531.09 | 2019-2025 | |
| Abbott Laboratories | $481.89 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Perclose Prostyle |
| Glaxosmithkline, LLC. | $470.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $392.56 | 2019-2025 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $320.02 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $311.62 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $236.13 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $223.64 | 2020-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.